More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$38.60B
EPS
1.52
P/E ratio
30.4
Price to sales
12.91
Dividend yield
1.397%
Beta
0.370273
Previous close
$67.57
Today's open
$66.52
Day's range
$66.52 - $68.15
52 week range
$37.31 - $69.77
show more
CEO
Pablo Legorreta
Employees
100
Headquarters
New York, NY
Exchange
Nasdaq Global Select
Shares outstanding
573605303
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Why Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer Drug
Revolution Medicines' daraxonrasib has received FDA approval. Royalty Pharma estimates that the drug could produce peak revenues of $11 billion.
The Motley Fool • Nov 8, 2026

Royalty Pharma (RPRX) Upgraded to Buy: What Does It Mean for the Stock?
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Nov 6, 2026

Royalty Pharma Q3 Earnings Call Highlights
Royalty Pharma NASDAQ: RPRX reported third-quarter portfolio receipts of $890 million, up 9% from a year earlier, as growth in its diversified royalty portfolio offset declines in certain products. The company raised its full-year 2026 outlook for the third consecutive quarter, citing continued momentum in recurring royalty receipts.
MarketBeat • Nov 4, 2026

Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Royalty Pharma reports third quarter 2026 results
Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% Net cash provided by operating activities of $686 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
GlobeNewsWire • Nov 4, 2026

Royalty Pharma (RPRX) Q3 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.18 per share. This compares to earnings of $1.17 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 4, 2026

Royalty Pharma: Unique, Diversified Life Science And Biopharma Pure Play
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, offering investors exposure to blockbuster therapies and megatrend-driven growth. RPRX focuses on de-risked, post-proof-of-concept assets, delivering attractive risk-adjusted returns with a return on invested capital around 15% and equity returns near 21%. The business model is defensive, uncorrelated with macro trends, and benefits from scale, high operating margins, and expert capital allocation.
Seeking Alpha • Nov 4, 2026

Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Zacks Investment Research • Oct 30, 2026

Should You Buy Royalty Pharma Stock Before Nov. 4?
Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release. It's unclear whether the company will knock it out of the park this quarter, as was the case with Q2 2026.
The Motley Fool • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Royalty Pharma plc commission-free¹. Build wealth for the long term using automated trading and transfers.